High-sensitivity imaging of erlotinib in resected non-small-cell lung cancer

High-sensitivity imaging of erlotinib in resected non-small-cell lung cancer - High-sensitivity imaging of erlotinib in resected non-small-cell lung cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009745

Enrollment

Registered

2013-01-10

Start date

2012-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

medication of erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small-lung cancer, EGFR mutation positive, performance status 0-1

Exclusion criteria

Exclusion criteria: Case with serious complications

Design outcomes

Primary

Measure	Time frame
imaging of erlotinib in resected samples	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026